Evaxion Biotech A/S, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health (NIH) for the development of a lead vaccine candidate for gonorrhea.
Biovaxys Technology Corp. has announced that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University (OSU) to develop a pan-sarbecovirus vaccine.
Stemcyte Inc. has received IND approval from the FDA for a phase II trial using umbilical cord blood stem cell therapy for post-COVID syndrome, or long COVID.
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation.
Sirnaomics Ltd. reported progress with its Galahead RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases.
Treating mice with butyrate, a short-chain fatty acid that is normally produced by beneficial gut microbes, prevented anaphylactic shock in allergic mice when they were exposed to peanuts after treatment. It also reduced inflammation in animals with colitis.
To develop a safe and effective respiratory syncytial virus (RSV) vaccine for use in early life, Boston Children's Hospital scientists and their collaborators developed CAF-08, a liposomal formulation consisting of combined TLR7 (3M-052) and Mincle (trehalose-6,6-dibehenate [TDB]) agonists and the RSV pre-F antigen.
Blue Water Vaccines (BWV) will attempt to present monkeypox antigens within its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel monkeypox vaccine.
The U.S. Department of Defense (DoD) is awarding Codagenix USD 4.4 million for further development of its next-generation tetravalent dengue vaccine candidate CodaVax-DENV.
RSS
